Coveo Introduces Two New Groundbreaking GenAI Business Applications and 15+ AI Innovations in the New Coveo Spring Release
March 28, 2024 09:00 ET
|
Coveo Solutions Inc.
Innovations to Coveo’s Industry-Leading Enterprise AI Platform facilitate deployment of multi-channel enterprise-grade generative answering that delivers b
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
March 28, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 28, 2024 08:00 ET
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Dore Copper Identifies Gold Exploration Potential at Norhart Zone, Just North of the Former Joe Mann Mine
March 27, 2024 17:30 ET
|
DORÉ COPPER MINING CORP
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Doré Copper Mining Corp. (the "Company" or "Doré Copper") (TSXV: DCMC; OTCQX: DRCMF; FRA: DCM) reports that it has completed its first review of the...
Gaia Reports Fourth Quarter and Full Year 2023 Results
March 27, 2024 16:05 ET
|
Gaia, Inc.
BOULDER, Colo., March 27, 2024 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA) (“Gaia” or the “Company”), a conscious media and community company, reported financial results for the fourth quarter and...
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
March 26, 2024 06:30 ET
|
Praxis Precision Medicines, Inc.
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with...
Praxis Precision Medicines to Host PRAX-628 Program Update
March 25, 2024 16:01 ET
|
Praxis Precision Medicines, Inc.
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at...
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
March 21, 2024 07:30 ET
|
Absci Corporation
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened...
Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors
March 21, 2024 07:00 ET
|
Cancer Focus Fund; Eisbach Bio GmbH
Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
March 20, 2024 02:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult...